trial

Clozapine for Cannabis Use in Schizophrenia

NCTId NCT01639872
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 49 (actual)
Sponsored by Dartmouth-Hitchcock Medical Center
Primary completion 2017-03-29
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
49 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2013-05-01
Primary completion
2017-03-29
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
ClozapineRisperidone

Sponsors

Dartmouth-Hitchcock Medical CenterLead Sponsor
University of South CarolinaCollaborator
Michigan State UniversityCollaborator
University of MiamiCollaborator
University of Massachusetts, WorcesterCollaborator

Investigators

1
Alan I. Green, MDStudy Chair

Sites

9 total
Garden Grove, United StatesOakland, United StatesMiami, United StatesWorcester, United StatesGrand Rapids, United StatesLebanon, United StatesRaleigh, United StatesColumbia, United StatesRutland, United States

Facts & assertions

4 sourced
Enrollment
49
Phase
PHASE4
Primary Completion Date
2017-03-29
Status
COMPLETED
relationships
The graph out of here
drug
Clozapine
drug
Risperidone
drug
lead_sponsor
Dartmouth-Hitchcock Medical Center
company
collaborator
University of South Carolina
company
Michigan State University
company
indication
Marijuana Abuse
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Alan I. Green, MD
person